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Abstract: Persistence on treatment affects the efﬁ  cacy of antihypertensive treatment. We 
prospectively investigated the persistence on therapy and the extent of blood pressure (BP) 
control in 347 hypertensive patients (age 59.4 ± 6 years) randomly allocated to a ﬁ  rst-line 
treatment with: angiotensin-converting enzyme (ACE) inhibitors, calcium-channel blockers 
(CCBs), ß-blockers, angiotensin-II receptor blockers (ARBs), or diuretics and followed-up for 
24-months. Persistence on treatment was higher in patients treated with ARBs (68.5%) and 
ACE inhibitors (64.5%) vs CCBs (51.6%; p   0.05), β-blockers (44.8%, p   0.05), and diu-
retics (34.4%, p   0.01). No ARB, ACE inhibitor, β-blocker, or diuretic was associated with a 
higher persistence in therapy compared with the other molecules used in each therapeutic class. 
The rate of persistence was signiﬁ  cantly higher in patients treated with lercanidipine vs others 
CCBs (59.3% vs 46.6%, p   0.05). Systolic and diastolic BP was decreased more successfully 
in patients treated with ARBs (–11.2/–5.8 mmHg), ACE inhibitors (–10.5/–5.1 mmHg), and 
CCBs (–8.5/–4.6 mmHg) compared with ß-blockers (–4.0/–2.3 mmHg p   0.05) and diuretics 
(–2.3/–2.1 mmHg, p   0.05). No ARB, ACE inhibitor, β-blocker, or diuretic was associated 
with a higher BP control compared with the other molecules used in each therapeutic class. 
A trend toward a better BP control was observed in response to lercanidipine vs other CCBs 
(p = 0.059). The present results conﬁ  rm the importance of persistence on treatment for the 
management of hypertension in clinical practice.
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Introduction
Reduction of blood pressure (BP) level through antihypertensive drugs is associated 
with a signiﬁ  cant decrease in cardiovascular disease morbidity and mortality (JNC VII 
2003; Staessen et al 2005). A comprehensive review of the impact of antihypertensive 
treatment reports that nearly 75% of hypertensive patients worldwide actually do 
not achieve a satisfactory BP according to guidelines (Wolf-Maier et al 2004). This 
indicates that the actual beneﬁ  ts of BP-lowering treatment are less than predicted, with 
a persistently elevated morbidity and mortality (Erdine et al 2006) and an increase in 
health care costs (McCombs et al 1994) associated with hypertension.
A major (and modiﬁ  able) reason for lack of BP control is failure by patients to take 
the medications as prescribed. Appropriate use of medications includes compliance 
(taking medications at the prescribed intervals and dosing regimen) and persistence 
(continuous use of medications for the speciﬁ  ed treatment time period), which, for 
hypertension, should be maintained life-long (Burnier 2006). Poor compliance and per-
sistence with antihypertensive medications is one likely explanation for the discrepancy 
between the efﬁ  cacy of drug treatment established through clinical trials and the results 
observed in clinical practice (Fujita et al 2006). Compliance with antihypertensive Vascular Health and Risk Management 2007:3(6) 1000
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treatment is inﬂ  uenced by many factors, including tolerability 
of the medication, complexity of the drug regimen, cost of the 
therapy, characteristics of the medical system and physician, 
and the asymptomatic nature of hypertension (David 2006). 
In many hypertensive patients, poor compliance has been 
attributed to high rate of adverse effects and/or worsening 
of quality of life (Ambrosioni et al 2000).
Previous studies assessing determinants of the discontinu-
ation of drug therapy were often limited by small sample size, 
short duration of follow-up, and lack of generalizability to the 
population treated in community-practice settings. Indeed, 
most of these studies were conducted as part of large-scale 
clinical trials (SHEP Group 1991) or of speciﬁ  c population 
cohorts (Monane et al 1997; Okano et al 1997). In many 
instances, the studies were retrospective and pre-dated the 
introduction of the newest classes of better-tolerated antihy-
pertensive agents, such as the angiotensin II receptor blockers 
(ARBs) that are characterized by an improved tolerability 
when compared with the older ones such as diuretics and 
β-blockers (Jones et al 1995).
A retrospective study based on the analysis of reﬁ  ll 
records of outpatients (n = 21,723 subjects) who have recently 
started an antihypertensive therapy showed that the continu-
ation of the initially prescribed therapy can be inﬂ  uenced 
by the drug class. Indeed, the proportion of patients con-
tinuing with the initial class of antihypertensive drugs after 
12-months of follow-up was signiﬁ  cantly higher with ARBs 
(64% of patients) and angiotensin-converting enzyme (ACE) 
inhibitors (58%) in comparison with calcium-channel block-
ers (CCBs) (50%), β-blockers (43%), and thiazide diuretics 
(38%) (Blooms 1998). These results were also conﬁ  rmed 
in a large sample of the Italian population by analyzing all 
prescriptions of antihypertensive drugs by general practition-
ers over a 2-year period. The persistence on treatment was 
greater for patients starting with ARBs while the prescrip-
tion of diuretics or complex regimens was associated with a 
withdrawal of treatment in as much as 70% of the population 
(Poluzzi et al 2005).
However, none of these studies has prospectively 
investigated the problem of the persistence on treatment 
with the different classes of antihypertensive drugs or has 
assessed whether the differences in persistence on treatment 
might directly inﬂ  uence the extent of BP control in clinical 
practice. Furthermore, no data have been published about 
the possibility that differences in the long-term persistence 
on antihypertensive treatment can be detected among drugs 
with a different tolerability proﬁ  le within the same class. 
This could be a relevant problem for some families of 
antihypertensive drugs such as the dihydropyridines CCBs, 
which have evolved from the ﬁ  rst-generation, short-acting 
compounds, to agents with long plasma and receptor half-life 
with a more favorable clinical proﬁ  le and a better compliance 
(Messerli 2002).
The objective of the present study was to prospectively 
evaluate the long-term persistence on antihypertensive treat-
ment of different classes of ﬁ  rst-line antihypertensive drugs 
prescribed as monotherapy in patients with mild to moderate 
hypertension. A secondary aim was to investigate whether a 
difference in persistence on treatment inﬂ  uenced BP control.
Patients and methods
The study was carried out in a cohort of 347 uncompli-
cated mild to moderate hypertensive patients (systolic 
blood pressure [SBP] 140–159 mmHg and diastolic 
BP [DBP] 90–109 mmHg) consecutively referred to our 
Hypertension Clinic for a clinical evaluation of their 
hypertension. The following patient characteristics were 
used as inclusion criteria: (1) age  8 and  80 years, (2) no 
antihypertensive treatment during the last 6 months, (3) no 
history of major cardiovascular diseases (previous stroke, 
myocardial infarction, heart failure, major arrhythmias) 
requiring complex pharmacological treatment, (4) no history 
of intolerance or hypersensitivity for speciﬁ  c classes of 
antihypertensive drugs, (5) lack of compelling indications 
for a speciﬁ  c class of antihypertensive drugs according to 
ESH-ESC Guidelines (ESH-ESC 2003), (6) capacity to 
comply with the study protocol. Patients were randomly 
allocated to treatment with one of the following classes 
of antihypertensive drugs: ACE inhibitors, ARBs, CCBs, 
diuretics, and ß-blockers, according to a single-blind study 
design. Patients treated with CCBs were randomly stratiﬁ  ed 
to lercanidipine in comparison with any other CCB according 
to a 1:1.5 proportion so that 46 patients were ﬁ  nally treated 
with lercanidipine. No methodological constraint was applied 
to the choice of CCBs other than lercanidipine. Lercanidipine 
was chosen as comparator because of its apparently higher 
tolerability in respect of other dihydropyridines (Beckey et al 
2007). We have not carried out comparisons in the other used 
classes of antihypertensive drugs, because the internal differ-
ence in term of tolerability is not so objectively valuable.
Before the inclusion in the study all patients underwent 
a complete clinical cardiovascular examination including 
BP measurement and standard 12-lead electrocardiogram. 
Resting supine and standing SBP and DBP were measured 
by mercury sphygmomanometer to the nearest 2 mmHg. The 
mean of 3 consecutive BP determinations at 1-min intervals Vascular Health and Risk Management 2007:3(6) 1001
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was recorded. An identical procedure was used for the 
assessment of heart rate. Secondary causes of hypertension 
have been excluded with clinical and biochemical evaluation 
according to a standardized protocol including determination 
of plasma renin activity, plasma aldosterone, renal function, 
and electrolyte balance. Patients were followed up at 
6-month intervals and for a cumulative period of 24 months 
from randomization. BP and heart rate were measured at 
each scheduled visit according to the baseline procedure. 
At the same time-interval any change in the initially 
prescribed therapy and the relative causes were reported 
in the case report form. Persistence with antihypertensive 
treatment has been simply deﬁ  ned as the continued use of a 
medication or medications according to initial prescription 
(ie, no discontinuation) over the period of follow-up. Persist-
ence has been determined as a dichotomous variable at the 
speciﬁ  ed time-intervals of the protocol. The proportion of 
patients persistent at any scheduled interval and the average 
duration of persistence (ie, the average time from treatment 
initiation to discontinuation) were then calculated. In patients 
in whom the treatment was discontinued before the end of 
follow-up, persistence was quantiﬁ  ed as the time-interval 
between randomization and treatment discontinuation. If no 
discontinuation occurred, persistence was censored at the 
end of the follow-up. In those patients who did not show a 
signiﬁ  cant reduction of SBP values ( 10%) by monotherapy 
after 6 months of treatment, a second drug was added. For 
the purpose of the data analysis they have been considered 
according to their initial treatment allocation. Patients who 
needed the addition of a third drug to control BP have been 
excluded from the study.
The study protocol was approved by the Ethics Committee 
of the St. Orsola-Malpighi Hospital and all patients provided 
written informed consent to participate before inclusion in 
the study.
Outcome variables
The main study outcome was the proportion of patients 
who persisted with the initially prescribed antihyperten-
sive treatment in each drug class and over the cumulative 
period of 24 months. We considered as “not persistent” 
all those patients who withdrew from treatment as well as 
those who switched to a different class of drugs. Secondary 
objectives were: (1) the extent of SBP and DBP decrease 
in the different subgroups of patients, (2) the comparison 
between the persistence on treatment between patients treated 
with lercanidipine vs other ﬁ  rst-line antihypertensive drugs 
including the other CCBs.
Statistical analysis
Results are expressed as means ± SD. Statistical analysis 
was carried out by using a SPSS statistical package (version 
9.6.2 for Windows; SPSS Inc., Chicago, IL, USA). The study 
sample size was calculated according to the hypothesis of a 
difference between ARBs and diuretics of 25% in terms of 
persistence on treatment with an alpha-error of 0.05 and a 
power of the study of 80%. Drop-out rate was estimated at 
10%. The data have been analyzed according to an intention-
to-treat approach by considering any patients according to 
their initial drug allocation. Observed differences in continu-
ation of initial therapy were compared between ARBs and 
the antihypertensive drug class having the next highest rate 
of continuation using unadjusted, two-sided, chi-square tests 
and an alpha level of 0.05. The odds ratio (OR) for continu-
ation with the initial drug therapy was then calculated by 
logistic regression. Potential predictors of persistence tested 
in the logistic regression model included age ( 65 and 
 65-years), sex, antihypertensive drug class (ARBs, ACE 
inhibitors, CCBs, β-blockers, thiazide diuretics), and dosing 
frequency (once or twice per day). Conﬁ  dence intervals (CIs) 
for the estimated ORs and signiﬁ  cance tests for the differ-
ences from the null value were calculated using estimated 
standard errors.
Results
The baseline characteristics of the study population (n = 347) 
and the distribution of ﬁ  rst-line antihypertensive drugs are 
reported in Table 1. One-hundred and ninety-six patients 
were men and 151 were women. The mean age was 58 ± 6 
and 62 ± 5 years respectively: no differences were observed 
among the different subgroups for age, gender distribution, 
and baseline SBP and DBP. Thiazide diuretic and non-
lercanidipine CCBs were equally prescribed as initial drug 
in 18.1% of the population, followed by ACE inhibitors and 
β-blockers (17.5%), and ARBs (15.2%). Lercanidipine was 
prescribed as ﬁ  rst-line antihypertensive therapy in 13.2% 
of patients. About 80% (78.1%) of the patients have been 
treated with monotherapy for the whole period of observa-
tion. Combination treatment was used in a small proportion of 
patients enrolled in the study (n = 15/347) without signiﬁ  cant 
differences among the various subgroups (Table 1) in the 
number of patients treated, antihypertensive drug distribu-
tion, or drop-in rate (data not shown).
At 24 months, the percentage of subjects continuing 
their initial ARB (68.5%) and ACE inhibitor (61.5%) medi-
cation was higher than the percentage of those continuing 
the treatment with CCBs (51.6%; p   0.05), β-blockers Vascular Health and Risk Management 2007:3(6) 1002
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(48.8%, p   0.05), and thiazide diuretics (34.4%, p   
0.01) (Figure 1). The main reason for drug discontinuation 
was the occurrence of adverse effects in over two-thirds 
of the population not achieving the primary end-point of 
persistence. The main duration of persistence with treat-
ment was: 20.3 ± 9 months for ARBs, 18.7 ± 8 months for 
ACE inhibitors, 17.1 ± 9 months for CCBs, and 15.8 ± 8 
and 14.1 ± 9 months for ß-blockers and thiazide diuretics, 
respectively (p   0.005 for trend). No ARB, ACE inhibitor, 
β-blocker, or diuretic was associated with a higher persist-
ence in therapy compared with the other molecules used 
in each therapeutic class. Among the subgroup of patients 
treated with CCBs the rate of stay-on-therapy was higher 
in those treated with lercanidipine (59.3% vs 46.6%, p   
0.05 vs others CCBs).
In the logistic regression model of persistence on treatment 
using ARBs as reference term, patients taking ACE inhibitors 
were more likely to continue their initial antihypertensive ther-
apy (ACE inhibitors: OR = 0.94, 95% CI: 0.79–0.99) followed 
by users of CCBs (OR = 0.76; 95% CI: 0.54–0.85), β-blockers 
(OR = 0.67; 95% CI: 0.57–0.79), and thiazide diuretics (OR = 
0.56; 95% CI: 0.38–0.84). Patients treated with lercanidipine 
(OR = 0.84, 95% CI: 0.61–0.88) were more likely to persist 
on treatment than patients taking other CCBs (OR = 0.70; 95% 
CI: 0.51–0.79). There was a clinically uncertain but statistically 
signiﬁ  cant relationship between female sex and continuation of 
the initial therapy (OR = 1.08; 95% CI: 1.02–1.15, p = 0.006). 
Age  65-years was associated with higher persistence (OR 
= 0.79; 95% CI: 0.74–0.84; p = 0.001) while the prescrip-
tion of drugs requiring multiple doses increased the rate of 
Table 1 Baseline characteristics of the population
 Diuretics  β-blockers ACEI  ARB  CCB  Overall
Pts  n.  63  61 61 53 63 347
Age (yr)  59.1 ± 5 59.7  ± 6 59.6  ± 5 58.9  ± 6 59.3  ± 6 59.4  ± 6
Age   65 yr (%)  21(33.3)  19 (31.1)  22 (36.0)  17 (32.0)  25 (39.7)  122 (35.1)
Gender  (M/F)  36/27  34/27 32/29 30/23 38/25 206/141
SBP (mmHg)  156 ± 15 157.2  ± 13 152.5  ± 12 154.3  ± 13 153.3  ± 12 154.1  ± 12
DBP (mmHg)  99.3 ± 9 100.2  ± 7 98.7  ± 8 99.1  ± 7 97.4  ± 7 99.1  ± 7
Heart rate (bpm)  78 ± 3 77  ± 5 78  ± 5 76  ± 4 79  ± 5 78.2  ± 4
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; CCB, calcium-channel blocker.
Figure 1 Rate of persistence on treatment after 6,12, and 24 months in different subgroups of patients treated with angiotension-II receptor blockers (ARBs), angiotensin-
converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), lercanidipine, ß-blockers, and diuretics. *, **, ***p   0.05, 0.01, 0.005 vs ARBs.
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discontinuation when compared with once-daily dosing (OR 
= 1.40; 95% CI: 1.29–1.52; p = 0.0001).
The decrease of SBP and DBP in response to treatment 
was largely proportional to the rate of persistence on treatment 
and greater in patients treated with ARBs, ACE inhibitors, 
and CCBs (Figure 2). The difference was clearly enhanced in 
those patients in whom the initial treatment was not replaced 
by a different antihypertensive drug after discontinuation 
(Figure 3). No ARB, ACE inhibitor, β-blocker, or diuretic 
was associated with a higher BP control compared with the 
other molecules used in each therapeutic class. The treatment 
with lercanidipine was associated with a trend toward a better 
BP control vs other CCBs with a difference that achieved a 
statistical signiﬁ  cance after 24 months of treatment.
Figure 3 Systolic blood pressure decrease over 24 months in the selected population of patients allocated to different drug classes and not replacing the antihypertensive 
treatment after withdrawal.
*p   0.05 vs other drug classes.
Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin-II receptor blockers; CCBs, calcium channel blockers.
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Discussion
The results of the present study conﬁ  rm that the rate of per-
sistence on initial antihypertensive treatment is prospectively 
higher for hypertensive patients treated with ARBs and ACE 
inhibitors as ﬁ  rst-line drugs. The extent of persistence on 
treatment might signiﬁ  cantly differ within patients treated 
with compounds belonging to the same class of drugs but 
bearing a different tolerability proﬁ  le (eg, CCBs). In addi-
tion, the study supports the evidence that the extent of 
persistence on treatment inﬂ  uences the clinical outcome 
of antihypertensive therapy, with a larger BP decrease in 
those patients treated with drugs leading to a higher rate of 
stay-on-therapy.
The present ﬁ  ndings are in agreement with previously 
published data demonstrating that the highest rate of long-
term (24 months) compliance with antihypertensive therapy 
can be achieved in patients treated with drugs inhibiting 
the renin-angiotensin system and CCBs (Blooms 1998). 
Conversely, Jones et al (1995), who analyzed the United 
Kingdom MediPlus primary care database, excluded any 
signiﬁ  cant difference in the 6-month rate of continuation 
in patients treated with the four major classes of antihyper-
tensive drugs (ie, thiazide diuretics, beta-blockers, calcium 
antagonists, and ACE inhibitors). Unfortunately, most of 
the available data are retrospective in nature (Blooms 1998; 
Perrault et al 2005) or based on a short period of observation 
(Jones 1995) and do not allow any deﬁ  nite conclusion about 
the differences in persistence with the antihypertensive 
treatment in clinical practice. Some prospective evidence 
might be achieved by the analysis of data collected in clinical 
trials that usually describe a rate of persistence higher than 
that reported by the present study and ranging from 80% to 
90% over a period of 3–5 years (Black et al 1987; Grimm 
et al 1997). However, large-scale clinical trials usually tend 
to overestimate the rate of persistence on antihypertensive 
treatment because of selection bias and behavior reinforce-
ment. And consequently their results cannot be directly 
applied to clinical practice. The results of the present study 
have been achieved in a sample of unselected hypertensive 
patients, treated in agreement with the ESH-ESC European 
Guidelines (ESH-ESC 2003), and describe a situation largely 
comparable with the real setting of daily clinical practice.
Interestingly, our results conﬁ  rm that the rate of stay-
on-therapy is higher for the patients treated with the better-
tolerated antihypertensive drugs (eg, ARBs, ACE inhibitors). 
This is in agreement with the clinical observation that for 
many patients the worsening of the quality of life that 
follows the use of antihypertensive medications is even more 
disturbing than the symptomless elevation of BP and might 
result in the discontinuation of poorly tolerated drugs. We 
also suggest the possibility that the relationship between the 
tolerability proﬁ  le of a drug and the patient’s persistence on 
treatment might be demonstrated within the same class of 
antihypertensive drugs. In particular a direct comparison 
of patients allocated to treatment with CCBs showed a 
greater persistence on therapy in those subjects treated with 
lercanidipine whose tolerability proﬁ  le has been repeatedly 
demonstrated to be superior when compared with other drugs 
of the same class (Bang et al 2003; Borghi 2005).
Our ﬁ  ndings suggest the importance of persistence on 
treatment for the management of hypertension. In particular, 
the higher the proportion of patients who persist on treatment 
the greater the BP decrease in response to antihypertensive 
drugs. This supports the hypothesis that the overall impact of 
the BP-lowering treatment in clinical practice may actually 
result from the interaction between the absolute antihyperten-
sive effect of drugs and their capacity to positively promote 
the persistence on treatment. In the hypertensive cohort of 
the Brisighella Heart Study the proportion of patients who 
achieved effective BP control over time was directly pro-
portional to the use of ACE inhibitors as ﬁ  rst-line drugs and 
inversely related to the prescription of diuretics (Borghi et al 
2004). The better BP control was associated with a lower rate of 
major cardiovascular events, including coronary artery disease 
and stroke. Unfortunately, no information on compliance with 
treatment has been collected in the Brisighella study and, as 
with all epidemiologic observational studies, this hypothesis 
requires conﬁ  rmation in other investigational settings.
Some limitations could reduce the conﬁ  dence in our 
observations. In the present study the rate of compliance to 
treatment was assessed only indirectly as the rate of discon-
tinuation of prescribed treatment and we do not have any 
speciﬁ  c information about prescription ﬁ  lling or pill count. 
However, the study was aimed at investigating the extent of 
persistence on treatment in the “real world” and for this reason 
we have decided to exclude from the protocol any measure of 
drug compliance and to focus on the rate of discontinuation 
as measure of “clinical” compliance. A further limitation is 
represented by the fact that the study has separately consid-
ered only one CCB (lercanidipine) to support the hypothesis 
that the persistence on treatment might signiﬁ  cantly differ 
among compounds belonging to the same class. The reason 
for such a choice was the large amount of data that suggests 
a measurable difference between the tolerability proﬁ  le of 
lercanidipine and other CCBs (Basile 2004). Since most of 
the difference is due to a lower rate of subjective adverse Vascular Health and Risk Management 2007:3(6) 1005
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events in patients treated with lercanidipine (from 40% to 
50%), this would have increased the chance of detecting a 
signiﬁ  cant difference in the proportion of patients persisting 
on the same treatment over time.
In conclusion, the results of the present study support 
a close relationship between the tolerability proﬁ  le of the 
different classes of antihypertensive drugs and the long-
term persistence on treatment; and show that the rate of 
stay-on-therapy can significantly differ among patients 
treated with several classes of ﬁ  rst-line antihypertensive 
drugs with different tolerability proﬁ  les even within the same 
pharmacological family, and that the higher the persistence 
on treatment the better the extent of BP control in clinical 
practice. Additional studies are needed to assess whether 
these differences will be maintained in the following years 
and whether the differences are associated with better health 
outcomes.
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